WALTHAM, Mass., June 3, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 4:00 p.m. EDT. Pieter Muntendam, President and CEO of BG Medicine, will be presenting on the Company's behalf. The presentation will be available to the public through a webcast accessible by visiting http://www.wsw.com/webcast/jeff60/bgmd/ or in the "Investors" section of the Company's website at www.bg-medicine.com. Replays will be available for 30 days after the presentation.
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine recently launched the galectin-3 test for use in patients with heart failure. The galectin-3 test is the first novel blood test for cardiac disease cleared by the FDA in five years. For additional information about BG Medicine and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8765